Hagop M. Kantarjian

Hagop M. Kantarjian is one of the most prolific and influential leukemia clinician-scientists in the world, serving as Professor and Chairman of the Department of Leukemia at MD Anderson Cancer Center for more than three decades. His research program has been central to defining optimal use of BCR-ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), establishing criteria for treatment response, molecular monitoring, and treatment-free remission that are now codified in international guidelines. He has participated in—and frequently led—the clinical trials that brought imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib from concept to approved therapies. Kantarjian's contributions to CML are paralleled by an equally substantial body of work in AML, MDS, and ALL. He led the pivotal trials of azacitidine and decitabine in MDS, and has been instrumental in defining the role of hypomethylating agents as the backbone of MDS and AML therapy in older patients. In ALL, he championed hyper-CVAD and blinatumomab-based regimens that markedly improved outcomes for adults with this disease. His department at MD Anderson functions as one of the world's largest academic leukemia programs, treating hundreds of patients through investigational trials annually and generating a disproportionate share of the world's leukemia clinical literature. Kantarjian is known for advocacy on behalf of patients regarding drug pricing and access, having authored high-profile commentaries in major journals calling for reform in oncology drug pricing practices. He has been recognized repeatedly for exceptional mentorship and has trained more leukemia specialists than perhaps any other individual in the field. His commitment to making clinical research available to patients regardless of socioeconomic background reflects his broader conviction that scientific excellence must be paired with social responsibility.